Bivalirudin Powder Cas No.128270-60-0
Khoom Source: Synthetic
Cov ntsiab lus ntawm cov khoom: Ntau dua lossis sib npaug li 98%
CAS Nr .: 128270-60-0
Txoj kev kuaj pom: HPLC
Cov khoom xyaw nquag: Cetrorelix Acetate
Cov khoom zoo: Dawb rau tawm dawb
Cov khoom mesh: 80-120 mesh
Kev Siv Khoom Siv: Kev pabcuam kev ua menyuam yaus (ART), kev kho mob gynecological, kev tshawb fawb lub hom phiaj
Khoom ntim: Lyophilized hmoov: Feem ntau ntim rau hauv iav ampoules lossis txhuas ntawv ci hnab, nrog lub peev xwm ntawm txhua lub raj mis / lub hnab customized raws li qhov yuav tsum tau muaj (xws li 1mg, 5mg, 10mg, thiab lwm yam)
Daim ntawv ua kua: Yuav tsum tau txhaj tshuaj sterile vials lossis vials, nrog hnyav ntim cais
Khoom Cia: Feem ntau khaws cia rau hauv lub teeb - pov thawj, kaw ib puag ncig ntawm 2-8℃.
Txee Lub neej: Thaum tsis qhib thiab khaws cia ntawm 2-8℃hauv lub teeb pom kev zoo, lub txee lub neej feem ntau yog 2-3 xyoos.
Khoom Description
High-Quality, Siab-Purity Bivalirudin Powder
Peb cov hmoov bivalirudin yog tus cwj pwm los ntawm siab purity thiab superior zoo, nruj me ntsis ua raws li kev cai thoob ntiaj teb kev tsim tshuaj. Nws purity yog validated los ntawm HPLC (High Performance Liquid Chromatography) thiab loj spectrometry tsom xam, ua tau raws li qhov yuav tsum tau ntawm USP/NF, EP, thiab ChP pharmacopoeias.
Peb cov khoom muab cov khoom sib xws - mus rau -batch zoo, nruj impurity tswj (tag nrho impurities<0.1%), and cGMP-compliant manufacturing processes, meeting the high standards demanded by global pharmaceutical companies and healthcare institutions.
Pharmacological teebmeem
Direct thrombin inhibition:Muaj peev xwm inhibits ob qho tib si dawb thiab fibrin -bound thrombin (Factor IIa), thaiv cov fibrinogen hloov mus rau fibrin thiab inhibiting platelet activation / aggregation.
Rov qab thiab luv luv - cov teebmeem ua yeeb yam:Ib nrab -lub neej ≈25 min (lub raum ua haujlwm li qub); rov kho sai ntawm coagulation post-discontinuation.
ATIII-kev ywj pheej mechanism:Kev ua tau zoo tsis cuam tshuam los ntawm qib antithrombin III.
Mechanism ntawm Action
Bivalirudin khi thrombin ntawm dual -kev sib cuam tshuam ntawm qhov chaw:
Catalytic site:Blocks substrate (xws li, fibrinogen) cleavage.
Anion-binding exosite I: Enhances affinity, stabilizing lub inhibitor complex.
Tus kheej - txwv cov khoom:Thrombin ib nrab cleaves bivalirudin's N-terminus, txo qis tshaj -kev pheej hmoo tiv thaiv coagulation.
Npaj siv
|
Cov neeg mob/Scenario |
Kev kho tus nqi |
|
Cov neeg mob PCI |
Heparin lwm txoj hauv kev, tshwj xeeb tshaj yog rau HIT-cov neeg mob uas xav tias yuav tsum tau lees paub; txo qhov kev pheej hmoo los ntshav. |
|
Mob Coronary Syndrome (ACS) |
Adjunct to antiplatelet therapy (aspirin/clopidogrel) in UA/NSTEMI. |
|
ECMO anticoagulation |
↓ Mortality (OR=0.74) thiab ↓ thrombotic xwm txheej (OR=0.52) vs. heparin; ↑ Kev vam meej. |
|
Siab - los ntshav- cov neeg mob txaus ntshai |
↓ Intracranial hemorrhage (kev pheej hmoo txo 4.9%) hauv cov neeg laus / lub raum tsis zoo. |
Kev ua tau zoo & Cov ntawv thov tseem ceeb
PCI / ACS:
↓ Loj los ntshav los ntawm 28% vs. heparin ± GPI (P=0.001; HORIZONS-AMI sim).
Mob stent thrombosis txaus ntshai marginally ↑ (P<0.0001), modifiable via prolonged infusion.
ECMO:
↓ Kev tuag los ntawm 26% (LOSSIS=0.74) thiab ↑ kev ua tiav tiav los ntawm 87% (OR=1.87).
Lub raum tsis zoo: Muaj kev nyab xeeb nrog kev hloov kho koob tshuaj (tsis txhob yog CrCl<30 mL/min).
Clinical Advantages Summary
|
Parameter |
Bivalirudin |
Heparin |
|
Los ntshav txaus ntshai |
Tsawg heev |
Siab dua |
|
HIT kev pheej hmoo |
Tsis muaj (kev nyab xeeb rau cov neeg mob HIT) |
Yuav tsum tau saib xyuas |
|
Anticoagulation tswj |
Luv ib nrab-lub neej; rov qab sai |
Variable teb; protamine thim rov qab |
|
Thrombin inhibition |
Dawb + fibrin - khi thrombin |
Dawb thrombin nkaus xwb |
Cim npe nrov: bivalirudin hmoov cas no.128270-60-0, Tuam Tshoj bivalirudin hmoov cas no.128270-60-0 manufacturers, lwm tus, Hoobkas
You Might Also Like
Xa kev nug